Company intelligence / Profile preview

JAPO

Ownership: Private
Development stage: Other

Overview

JAPO is an early-stage biotechnology company focused on the discovery and development of novel therapeutic agents for oncology and infectious diseases. The company utilizes a proprietary discovery platform to identify high-affinity molecules targeting previously undruggable or challenging biological pathways. JAPO's research emphasizes the integration of computational modeling with high-throughput screening to accelerate the transition from lead identification to pre-clinical validation. Currently, the company is advancing several internal programs while seeking strategic partnerships to expand its pipeline breadth.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on JAPO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JAPO.

Explore the full profile